Chemotargets, a CataloniaBio & HealthTech member, has opened a €5-15 million round of investment to shift its business model from software to biotechnology.
Founded in 2006 as a spin-off of the Systems Pharmacologylabatthe Hospital del Mar Research Institute, Chemotargets is expanding its activity to include drug discovery in several therapeutic areas, starting with oncology.
At the same time, Chemotargets will continue providing the sector with its smart technology and predictive drug design platforms (ClarityⓇ, with the European Commission Seal of Excellence, and ProSurfScan).
To consolidate this transformation, the company is being advised by the Genesis Biomed consultancy firm and Crea Inversión corporate funding firm. This shift will also come with changes in the management team, with Jordi Mestres as Chief Science Officer and a new CEO from the pharmaceutical industry.
Chemotargets currently has a team of 12 and posted €0.8 million in revenue in 2019.
Photo: Jordi Mestres, founder and CEO of Chemotargets at the Barcelona Science Park.
Comments